Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder

AIMS: To assess the long‐term safety of subcutaneous buprenorphine (CAM2038) weekly and monthly depots. DESIGN: Phase 3, open‐label, observational, multi‐centre 48‐week trial (ClinicalTrials.gov NCT02672111). SETTING: Twenty‐six out‐patient sites (United States, United Kingdom, Hungary, Denmark, Swe...

Descripción completa

Detalles Bibliográficos
Autores principales: Frost, Michael, Bailey, Genie L., Lintzeris, Nicholas, Strang, John, Dunlop, Adrian, Nunes, Edward V., Jansen, Jakob Billeskov, Frey, Lars Chemnitz, Weber, Bernd, Haber, Paul, Oosman, Sonia, Kim, Sonnie, Tiberg, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771955/
https://www.ncbi.nlm.nih.gov/pubmed/31013390
http://dx.doi.org/10.1111/add.14636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771955/
https://www.ncbi.nlm.nih.gov/pubmed/31013390
http://dx.doi.org/10.1111/add.14636

Ejemplares similares